Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | HTT | P42858 | 5/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347362 | 0.76 | SMN1; SMN2 (0.59) | MAPTHTTLMNANPSR1ALDH1A1 | |
| SCHEMBL25429481 | 0.76 | MKNK1 (0.47) | MAPTHTTLMNANPSR1TDP1 | |
| SCHEMBL3156019 | 0.75 | MAPT (0.52) | MAPTLMNANPSR1ALDH1A1TDP1 | |
| SCHEMBL5867591 | 0.74 | CDK2 (0.63) | — | |
| SCHEMBL3387040 | 0.73 | MAPT (0.49) | MAPTLMNANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25337758 | 0.71 | MAPT (0.43) | MAPTLMNANPSR1ALDH1A1POLB | |
| SCHEMBL5287550 | 0.69 | HCAR2 (0.43) | MAPTHTTPIK3C3LMNANPSR1 | |
| SCHEMBL10912996 | 0.69 | HSPB1 (0.41) | MAPTLMNANPSR1ALDH1A1TDP1 | |
| SCHEMBL57586 | 0.69 | PIK3C3 (0.53) | PIK3C3IGF1R | |
| SCHEMBL27690862 | 0.68 | IGF1R (0.59) | PIK3C3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4472959-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148481-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | SMO, SHH, GLI1 | MAPT 4299/4885HTT 3693/4885PIK3C3 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.